Patent application number | Description | Published |
20090155165 | ANTI-IGF-I RECEPTOR ANTIBODY - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 06-18-2009 |
20090162284 | ANTI-IGF-I RECEPTOR ANTIBODY - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 06-25-2009 |
20100009439 | ANTI-IGF-I RECEPTOR ANTIBODIES, DNAs, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS - DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 01-14-2010 |
20100260678 | ANTI-IGF-I RECEPTOR ANTIBODIES - Antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma, prostate cancer and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 10-14-2010 |
20130295050 | ANTI-IGF-I RECEPTOR ANTIBODIES, DNAS, VECTORS, HOST CELLS AND GENETIC CONSTRUCTS - DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor. | 11-07-2013 |
Patent application number | Description | Published |
20110158183 | METHOD AND APPARATUS FOR ENABLING REGISTRATION OF AGGREGATE END POINT DEVICES THROUGH PROVISIONING - A method and apparatus for enabling registration of an Aggregate End Point (AEP) device that is incapable of supporting a Session Initiation Protocol (SIP) based Internet Protocol Multimedia Subsystem (IMS) registration are disclosed. The method performs a static registration of the AEP device in a plurality of network elements associated with an Internet Protocol Multimedia Subsystem (IMS) network by provisioning. The method then processes an originating call request or a terminating call request associated with the AEP device using the static registration. | 06-30-2011 |
20110158236 | METHOD AND APPARATUS FOR PROCESSING A CALL TO AN AGGREGATE ENDPOINT DEVICE - A method and an apparatus for processing a call to an aggregate endpoint device over a network are disclosed. For example, the method receives a session request by an application server, wherein a route header for the session request comprises an aggregate endpoint identifier, and determines at least one Public User Identity (PUID) of the aggregate endpoint device in accordance with the aggregate endpoint identifier. The method obtains a Serving-Call Session Control Function Fully Qualified Domain Name (S-CSCF FDQN) of a Serving-Call Session Control Function (S-CSCF) that performs a termination processing for the aggregate endpoint device, and forwards the session request to the S-CSCF with a route header that comprises the PUID of the aggregate endpoint device. | 06-30-2011 |
20110161505 | METHOD AND APPARATUS FOR PROCESSING A CALL TO AN AGGREGATE ENDPOINT DEVICE - A method and an apparatus for processing a call to an aggregate endpoint device over a network are disclosed. For example, the method receives a session request by a Serving-Call Session Control Function (S-CSCF), wherein a route header for the session request comprises an aggregate endpoint identifier, and interacts with an application server to receive a Public User Identity (PUID) of the aggregate endpoint device in accordance with the aggregate endpoint identifier. The method performs a termination processing for the session request using the PUID of the aggregate endpoint device, and forwards the session request towards the aggregate endpoint device. | 06-30-2011 |
20110161519 | METHOD AND APPARATUS FOR PROVIDING A TRANSIT SERVICE FOR AN AGGREGATE ENDPOINT - A method and an apparatus for providing a transit service in a communications network are disclosed. For example, the method receives a session request by a routing device, where the session request is directed towards a user endpoint device that accesses one or more services via the aggregate endpoint device, and interrogates a Home Subscriber Server (HSS) for domain information of the aggregate endpoint device. The method determines if the domain information of the aggregate endpoint device is associated with a transit function, and routes the session request to the transit function for completion, if the domain information of the aggregate endpoint device is associated with the transit function. | 06-30-2011 |
20130215882 | METHOD AND APPARATUS FOR ENABLING REGISTRATION OF AGGREGATE END POINT DEVICES THROUGH PROVISIONING - A method and apparatus for enabling registration of an Aggregate End Point (AEP) device that is incapable of supporting a Session Initiation Protocol (SIP) based Internet Protocol Multimedia Subsystem (IMS) registration are disclosed. The method performs a static registration of the AEP device in a plurality of network elements associated with an Internet Protocol Multimedia Subsystem (IMS) network by provisioning. The method then processes an originating call request or a terminating call request associated with the AEP device using the static registration. | 08-22-2013 |
20140334426 | METHOD AND APPARATUS FOR PROCESSING A CALL TO AN AGGREGATE ENDPOINT DEVICE - A method and an apparatus for processing a call to an aggregate endpoint device over a network are disclosed. For example, the method receives a session request by a Serving-Call Session Control Function (S-CSCF), wherein a route header for the session request comprises an aggregate endpoint identifier, and interacts with an application server to receive a Public User Identity (PUID) of the aggregate endpoint device in accordance with the aggregate endpoint identifier. The method performs a termination processing for the session request using the PUID of the aggregate endpoint device, and forwards the session request towards the aggregate endpoint device. | 11-13-2014 |
20160036867 | METHOD AND APPARATUS FOR ENABLING REGISTRATION OF AGGREGATE END POINT DEVICES THROUGH PROVISIONING - A method and apparatus for enabling registration of an Aggregate End Point (AEP) device that is incapable of supporting a Session Initiation Protocol (SIP) based Internet Protocol Multimedia Subsystem (IMS) registration are disclosed. The method performs a static registration of the AEP device in a plurality of network elements associated with an Internet Protocol Multimedia Subsystem (IMS) network by provisioning. The method then processes an originating call request or a terminating call request associated with the AEP device using the static registration. | 02-04-2016 |
Patent application number | Description | Published |
20100189651 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 07-29-2010 |
20100221212 | PROPROTEINS AND METHODS OF USE THEREOF - The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins. | 09-02-2010 |
20120149061 | Modified Antibody Compositions, Methods of Making and Using Thereof - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 06-14-2012 |
20120207756 | Modified Antibody Compositions, Methods of Making and Using Thereof - The present disclosure provides modified antibodies which contain an antibody or antibody fragment (AB) modified with a masking moiety (MM). Such modified antibodies can be further coupled to a cleavable moiety (CM), resulting in activatable antibodies (AAs), wherein the CM is capable of being cleaved, reduced, photolysed, or otherwise modified. AAs can exhibit an activatable conformation such that the AB is more accessible to a target after, for example, removal of the MM by cleavage, reduction, or photolysis of the CM in the presence of an agent capable of cleaving, reducing, or photolysing the CM. The disclosure further provides methods of making and using such modified antibodies and activatable antibodies. | 08-16-2012 |
20130101555 | Proproteins and Methods of Use Thereof - The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins. | 04-25-2013 |
20150203559 | PROPROTEINS AND METHODS OF USE THEREOF - The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e. a full length protein or functional fragment thereof) which is coupled to a peptide mask that inhibits the binding of the functional protein to its target or binding partner. An activatable proprotein contains a functional protein coupled to a peptide mask, and further coupled to an activatable linker, wherein in an non-activated state, the peptide mask inhibits binding of the functional protein to its target or binding partner and in an activated state the peptide mask does not inhibit binding of the functional protein to its target or binding partner. Proproteins can provide for reduced toxicity and adverse side effects that could otherwise result from binding of a functional protein at non-treatment sites if it were not inhibited from binding its binding partner. Proproteins can further provide improved biodistribution characteristics. Proproteins containing a peptide mask can display a longer in vivo or serum half-life than the corresponding functional protein not containing a peptide mask. The disclosure further provides methods of screening for, making, and using these proproteins. | 07-23-2015 |